Product Name: Human PTPRC / CD45 Antibody (Novartis patent anti-CD45, Research Use)
Catalog Number: NBR-0740
Target Name: PTPRC / CD45
Trade Name: Novartis patent anti-CD45
Antibody Drug Description: The drug is a recombinant fully human anti-CD45 monoclonal antibody, being developed by Novartis. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: PTPRC
Synonyms: T200; GP180; CD45; LCA; IMD105; B220
Target Description: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Ensembl: ENSG00000081237
Uniprot: P08575